Raymond James Financial reissued their buy rating on shares of Vital Therapies (NASDAQ:VTL) in a research note released on Tuesday.

A number of other equities research analysts have also recently weighed in on VTL. BidaskClub cut Vital Therapies from a buy rating to a hold rating in a research note on Thursday, November 9th. Zacks Investment Research cut Vital Therapies from a hold rating to a sell rating in a research report on Thursday, October 5th. Finally, ValuEngine cut Vital Therapies from a sell rating to a strong sell rating in a research report on Friday, November 17th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $8.00.

Vital Therapies (NASDAQ:VTL) traded down $0.10 on Tuesday, reaching $4.90. The company had a trading volume of 352,529 shares, compared to its average volume of 162,195. Vital Therapies has a twelve month low of $2.25 and a twelve month high of $6.50.

Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. During the same period in the prior year, the firm posted ($0.32) earnings per share. equities analysts expect that Vital Therapies will post -1.26 earnings per share for the current year.

In other news, Director Jean Jacques Bienaime acquired 10,000 shares of the stock in a transaction on Wednesday, September 13th. The shares were purchased at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the transaction, the director now directly owns 65,119 shares of the company’s stock, valued at $260,476. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Muneer A. Satter acquired 130,000 shares of the stock in a transaction on Thursday, September 14th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $521,300.00. The disclosure for this purchase can be found here. 32.60% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTL. Goldman Sachs Group Inc. grew its holdings in shares of Vital Therapies by 261.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after purchasing an additional 168,705 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of Vital Therapies during the 2nd quarter worth $396,000. Granahan Investment Management Inc. MA grew its holdings in shares of Vital Therapies by 51.4% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock worth $1,961,000 after purchasing an additional 131,828 shares in the last quarter. Susquehanna International Group LLP acquired a new stake in shares of Vital Therapies during the 2nd quarter worth $268,000. Finally, Dowling & Yahnke LLC acquired a new stake in shares of Vital Therapies during the 3rd quarter worth $252,000. 24.35% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Vital Therapies’ (VTL) “Buy” Rating Reiterated at Raymond James Financial” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/09/vital-therapies-vtl-buy-rating-reiterated-at-raymond-james-financial.html.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Stock Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related stocks with our FREE daily email newsletter.